| pubmed-article:7711417 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C0150097 | lld:lifeskim |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C0017245 | lld:lifeskim |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C0085542 | lld:lifeskim |
| pubmed-article:7711417 | lifeskim:mentions | umls-concept:C1704417 | lld:lifeskim |
| pubmed-article:7711417 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:7711417 | pubmed:dateCreated | 1995-5-18 | lld:pubmed |
| pubmed-article:7711417 | pubmed:abstractText | Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia. | lld:pubmed |
| pubmed-article:7711417 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7711417 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7711417 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7711417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7711417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7711417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7711417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7711417 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7711417 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:7711417 | pubmed:issn | 0941-0198 | lld:pubmed |
| pubmed-article:7711417 | pubmed:author | pubmed-author:FaergemanOO | lld:pubmed |
| pubmed-article:7711417 | pubmed:author | pubmed-author:MeinertzHH | lld:pubmed |
| pubmed-article:7711417 | pubmed:author | pubmed-author:GerdesL ULU | lld:pubmed |
| pubmed-article:7711417 | pubmed:author | pubmed-author:KlausenI CIC | lld:pubmed |
| pubmed-article:7711417 | pubmed:author | pubmed-author:HansenP SPS | lld:pubmed |
| pubmed-article:7711417 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7711417 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:7711417 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7711417 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7711417 | pubmed:pagination | 1065-70 | lld:pubmed |
| pubmed-article:7711417 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:meshHeading | pubmed-meshheading:7711417-... | lld:pubmed |
| pubmed-article:7711417 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7711417 | pubmed:articleTitle | Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study. | lld:pubmed |
| pubmed-article:7711417 | pubmed:affiliation | Department of Internal Medicine and Cardiology A, Aarhus Amtssygehus University Hospital, Denmark. | lld:pubmed |
| pubmed-article:7711417 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7711417 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7711417 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7711417 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
